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SUMMARY
The clostridium-like ecto-ADP-ribosyltransferase
ARTC1 is expressed in a highly restricted manner in
skeletal muscle and heart tissue. Although ARTC1
is well studied, the identification of ARTC1 targets
in vivo and subsequent characterization of ARTC1-
regulated cellular processes on the proteome
level have been challenging and only a few ARTC1-
ADP-ribosylated targets are known. Applying our
recently developed mass spectrometry-based work-
flow to C2C12 myotubes and to skeletal muscle and
heart tissues from wild-type mice, we identify hun-
dreds of ARTC1-ADP-ribosylated proteins whose
modifications are absent in the ADP-ribosylome of
ARTC1-deficient mice. These proteins are ADP-ribo-
sylated on arginine residues and mainly located on
the cell surface or in the extracellular space. They
are associated with signal transduction, trans-
membrane transport, and muscle function. Valida-
tion of hemopexin (HPX) as a ARTC1-target protein
confirmed the functional importance of ARTC1-
mediated extracellular arginine ADP-ribosylation at
the systems level.
INTRODUCTION
Protein ADP-ribosylation is an ancient post-translational modifi-
cation (PTM) found in a wide range of biological species (Corda
and Di Girolamo, 2003; Koch and R€uger, 1994; Ueda and
Hayaishi, 1985). ADP-ribosylation has been shown to regulate
several cellular processes by altering the function of themodified
protein and/or providing a scaffold for the recruitment of other
proteins. ADP-ribosylation can be divided into two subtypes:
mono-ADP-ribosylation (MARylation), in which only mono-
ADP-ribose (MAR) is transferred to an amino acid of a target pro-
tein, and poly-ADP-ribosylation (PARylation), which involves the
addition of further ADP-ribose (ADPr) moieties to generate poly-
ADP-ribose (PAR) (Hottiger, 2015). In mammalians, these modi-
fications are catalyzed by ADP-ribosyltransferases (ARTs),
which are divided into two ART families, ARTC (C2/C3 toxin-
like, also ecto-ARTs) and ARTD (diphtheria toxin-like, formerly
PARPs), respectively (Hottiger et al., 2010). While all known en-
zymes catalyzing PARylation belong to the ARTD family, and
MARylation has traditionally been the domain of the ARTCs, it
has recently been appreciated that some ARTDs and even
some structurally unrelated sirtuins can alsomediateMARylation
(Feijs et al., 2013).
Four human (ARTC1, 3, 4, 5, formerly also hART1-5) and six
mouse (ARTC1, 2.1, 2.2, 3, 4, 5, formerly also mART1-5) ARTC
genes have been identified. For both species, ARTC1 is ex-
pressed mainly in skeletal and heart muscles, non-lactated
mammary gland, brown adipocytes, epithelial cells, or activated
granulocytes (Braren et al., 1998; Glowacki et al., 2002; Koch-
Nolte et al., 2006). The ARTC family members ARTC1–ARTC4
are expressed as glycosylphosphatidylinositol (GPI)-anchored
ecto-enzymes (Glowacki et al., 2001, 2002; Hottiger et al.,
2010; Koch-Nolte et al., 2006). ARTC1, 2, and 5 contain the char-
acteristic cholera toxin R-S-E catalytic motif in their active cen-
ter. R and S are important for NAD+ binding and E has a catalytic
function (Laing et al., 2011). Arginine-specificMARylation activity
has been confirmed for human andmouse ARTC1 and ARTC5 as
well as the two mouse proteins of ARTC2.1 and ARTC2.2 (Glo-
wacki et al., 2002).
An important question when examining the biological function
of ARTCs is the endogenous source of extracellular NAD+ under
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normal and pathophysiological conditions, since NAD+ is not cell
membrane permeable and the extracellular and plasma levels of
NAD+ are lower than intracellular NAD+ concentrations (Davies
et al., 1999; Haag et al., 2007; Koch-Nolte et al., 2011). However,
NAD+ can be released from intracellular sources during lytic
processes, hypoxia, and inflammation (Adriouch et al., 2007;
Bruzzone et al., 2001; Haag et al., 2007; Scheuplein et al.,
2009; Seman et al., 2004). The net biological effect of extracel-
lular NAD+ therefore depends on the amount of NAD+ released
into the extracellular space, the quality and quantity of specific
receptors/enzymes expressed, and on the activities of the
catabolizing-enzymes (Haag et al., 2007; Koch-Nolte and Zie-
gler, 2013).
Functional consequences of eukaryotic arginine ADP-ribosy-
lation have mainly been studied for ARTC2.2 targets such as
the ion channel P2X7. MARylation of R125 of P2X7 leads to its
activation (Adriouch et al., 2008) and subsequent inflammasome
activation, processing, and cytokine release (IL-1b, IL-18, IL-1
receptor antagonist and IL-36a), as well as release and activation
of proteases (mainly ADAM10 and 17) resulting in the shedding
of cell surface molecules, including ARTC2.2 itself (Bartlett
et al., 2014; Menzel et al., 2015). Prolonged activation of P2X7
stimulates T cell death, also called NAD+-induced cell death
(NICD) (Adriouch et al., 2007). As for ARTC1, which was found
in bronchoalveolar lavage fluid from smokers, it was reported
to modify the defensin human neutrophil peptide 1 (HNP1) on
Arg14 and Arg24, which specifically reduces its antimicrobial
and cytotoxic activities (Paone et al., 2002; Stevens et al.,
2009). ARTC1 ADP-ribosylation was also found to have a
role in endoplasmic reticulum (ER) stress responses (Fabrizio
et al., 2015). In addition, ARTC1 ADP-ribosylates members of
the integrin family of adhesionmolecules on skeletal muscle cells
and leukocytes (Zolkiewska and Moss, 1993). ADP-ribosylation
of integrin a7 (ITGA7) by ARTC1 modulates the binding of integ-
rin a7b1 to laminin (Okazaki and Moss, 1999).
Despite these recent discoveries, the substrates of the
different ARTCs aswell as their implications in cellular processes
are still not very well understood. Furthermore, it is also not
known whether ARTC1-mediated ADP-ribosylation has any
role under steady-state (i.e., basal) conditions. This is in large
part due to the fact that mass spectrometry (MS)-based
methods were only developed for and applied to the identifica-
tion of cell culture-derived ADP-ribosylated proteins and their
ADPr acceptor sites. Very recently, we developed an approach
that allowed the analysis of ADP-ribosylated proteins in the liver,
a tissue that has already been described to regulate cellular pro-
cesses in an ADP-ribosylation-dependent manner (Martello
et al., 2016). Interestingly, ARTC2.2 was found among the modi-
fied targets. Moreover, we have shown that the GPI-anchored
ARTC2.2 is restricted to a small subset of target proteins by its
association with lipid rafts but promiscuously modifies many
different targets upon detergent solubilization of the plasma
membrane (Bannas et al., 2005; Laing et al., 2011). It remained
so far unclear whether ARTC1 has a comparable target spec-
trum, or whether it would only modify a few specific target pro-
teins, as it has been observed for the bacterial ART toxins.
Here, we analyzed the ARTC1-specific ADP-ribosylome in
C2C12 myotubes as well as skeletal and heart muscle of wild-
type and ARTC1-deficient mice, which were generated to facili-
tate systems-level analyses. These studies revealed that ARTC1
is essential for the modification of numerous proteins under
basal conditions, which provides strong evidence for the
physiological importance of ARTC1. In particular, we show that
ARTC1-dependent ADP-ribosylation of hemopexin (HPX)
strongly reduces its capacity to bind heme, which is likely highly
relevant for the function of this strongest known heme binding
protein. We provide a comprehensive systems-level analysis
of an ARTC1-substrate relationship in vivo and map ARTC1-
mediated ADP-ribosylation in two different muscle tissues. The
site-specific profile of the ARTC1-dependent ADP-ribosylome
provides evidence for a widespread contribution of ADP-ribosy-
lation on the cell surface and the extracellular space and pro-
vides an extensive resource that allows to further discover the
functional relevance of ADP-ribosylation in muscle physiology
and pathophysiology.
RESULTS
ARTC1 Mediates Widespread Extracellular
ADP-Ribosylation in C2C12 Myotubes
To assess the extent of ARTC1-mediated ADP-ribosylation and
to identify ADP-ribosylated proteins, we first verified the expres-
sion of ARTC1 in differentiating C2C12 cells by qRT-PCR and
could confirm previous reports (Zolkiewska and Moss, 1993)
showing that ARTC1 is specifically expressed in mouse heart tis-
sue and C2C12 myotubes (Figure S1A). The other known active
membrane-bound extracellular ART expressed in mice is ARTC2
(Koch-Nolte et al., 2008). We were, however, unable to detect
ARTC2 in C2C12 myotubes by qRT-PCR (data not shown),
which is in agreement with the reports that ARTC2 is predomi-
nantly expressed in immune cells (Glowacki et al., 2002; Koch-
Nolte et al., 1999). ARTC3 is also present in C2C12 myotubes
as detected by a recent proteomics approach (Deshmukh
et al., 2015). ARTC3, however, lacks the catalytic R-S-E motif
and was therefore proposed to be catalytically inactive (Glo-
wacki et al., 2002). To determine whether ARTC3 is indeed inac-
tive, we employed DC27.10 cells, which were engineered to
stably overexpress ARTC1 or ARTC3 (Koch-Nolte et al., 2005).
We confirmed overexpression and localization of ARTC1 and
ARTC3 to the plasma membrane by flow cytometric analysis
(Figure S1B). Incubation of these cells with [32P]-NAD+ led to
strong ADP-ribosylation of cell surface proteins in the case of
ARTC1-overexpressing cells, but not in the case of ARTC3-over-
expressing or parental cells (Figure S1C). Next, we performed
small interfering RNA (siRNA)-mediated knockdown of endoge-
nous ARTC1 and ARTC3 in C2C12 myoblasts and subsequently
differentiated them to myotubes (Figure S1D). Addition of
[32P]-NAD+ to those myotubes revealed that cell surface ADP-
ribosylation in C2C12 myotubes is exclusively dependent on
ARTC1 (Figure S1E).
To assess the target space of ARTC1, we treated differenti-
ated C2C12 myotubes with NAD+ or left them untreated and
subsequently mapped site-specific ADP-ribosylation using our
established ADP-ribosylome proteomic workflow (Bilan et al.,
2017b; Martello et al., 2016). This method identifies the ADP-
ribosylated peptide sequence and the exact ADPr amino acid
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acceptor site with a high probability (mascot site localization
score, >90%) for 22% of the identified modified peptides in
this study. While only few modified peptides were identified
under basal (i.e., untreated) conditions, we identified a strong in-
crease in ADP-ribosylation following NAD+ treatment (144 versus
9 unique ADP-ribosylated peptides [Figure S2A]; 80 versus 7
ADP-ribosylated proteins [Figure 1A] corresponding to 120 ±
untreated NAD+
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Figure 1. Profiling of ADP-Ribosylation in
Mouse Myotubes
(A) Venn diagram of identified unique ADP-ribosy-
lated proteins in C2C12 myotubes left untreated or
treated with 50 mM NAD+.
(B) R-ADP-ribosylation is specifically induced upon
NAD+ treatment of C2C12 myotubes. Identified
unique ADPr acceptor sites in C2C12 myotubes left
untreated or treated with 50 mM NAD+ (n = 3; bar
graph represents mean and SD).
(C) GO term-enrichment analysis displaying signifi-
cantly enriched (p < 0.001) GO terms of the identified
ADP-ribosylated proteins (n = 85) according to their
cellular localization, molecular function, and the
biological processes. Term enrichment is calculated
relative to a deep C2C12 myotube proteome (n =
8,476) (Deshmukh et al., 2015). Numbers in paren-
theses indicate participation size and category size,
respectively.
(D) Unsupervised hierarchical clustering analysis
of normalized intensity values determined by MS1-
based label-free quantification of detected ADP-
ribosylation sites. A black cell corresponds to an
absent or a relatively low-abundant ADP-ribosylation
site, blue indicates a site of intermediate abundance,
and green indicates a highly abundant site.
Protein names for three indicated clusters,
where ADPr peptides are observed already under
untreated conditions are indicated. Names in bold
correspond to proteins with a function in biological
adhesion.
(E) STRING database analysis of high-confidence
protein interactions (interaction score, >0.7) between
identified ADP-ribosylated proteins in C2C12 cells.
Only ADP-ribosylated proteins with at least one
interaction with another ADP-ribosylated protein are
shown. Subcellular localization and biological pro-
cess are annotated.
See also Figures S1 and S2 and Table S1.
47 versus 9 ± 1 ADP-ribosylated peptide
spectramatches [Figure S2B]). Under these
conditions, arginine was identified as the
main ADPr-acceptor amino acid (Fig-
ure 1B). Gene ontology (GO) analyses
revealed that the NAD+ treatment-depen-
dent ADP-ribosylation targets are predom-
inantly extracellular and plasma membrane
proteins having a molecular function in
extracellular matrix binding and receptor
activity and participating in biological pro-
cesses associated with cell adhesion, mus-
cle contraction, and regulation of signal
transduction (Figure 1C).
To quantitatively assess the observed increase of ADP-ribosy-
lation, we performed label-free MS1-based quantification of all
identified ADP-ribosylated peptides using three biological repli-
cates of untreated and NAD+-treated C2C12 myotubes. A
good Pearson correlation of the ADP-ribosylated peptide abun-
dance among untreated (R > 0.76) and NAD+-treated (R > 0.87)
replicates, respectively, demonstrated that the measured
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ADP-ribosylated peptide signal intensities could be used as a
reliable measure for modification site abundance (Figure S2C).
Most detected ADP-ribosylated targets were strongly induced
upon NAD+ treatment and, importantly, are novel ARTC1 targets
(Figure 1D; Table S1). The heatmap representation of the ADP-
ribosylation site abundance reveals three minor clusters of sites
that were already stably ADP-ribosylated under basal conditions
(Figure 1D). From the indicated clusters, the ADP-ribosylated
peptides of the top and lower cluster were more abundantly
modified after NAD+ treatment and included four members of
the integrin family (ITGA7, ITGA6, ITGAV, and ITGB5) (Figure 1D),
with ITGA7 representing the only previously reported ARTC1
target (Zolkiewska and Moss, 1993). A small portion of the
ADP-ribosylation sites identified remained largely unchanged
following NAD+ treatment as visualized in the middle cluster.
This cluster included histone H2B, which however is unlikely a
target of ARTC1, since the two proteins are not in the same
cellular compartment (Leidecker et al., 2016; Martello et al.,
2016). Interestingly, most of the proteins of this small middle
cluster (approximately 80%) were annotated to be localized to
the endomembrane system, and thus likely not affected by addi-
tion of exogenous NAD+.
To understand whether several members of protein com-
plexes are targeted by ADP-ribosylation, wemapped and visual-
ized high-confidence interactions (minimum required interaction
scores, >0.7) between the ADP-ribosylated proteins identified
above using the STRING database of physical and functional
protein interactions (Szklarczyk et al., 2015). The analysis identi-
fied several protein interaction networks that were abundantly
ADP-ribosylated but revealed no significant enrichment of
ADP-ribosylation targeting multiple members of protein com-
plexes. We could unravel an interaction network of 13 ADP-ribo-
sylated proteins with a high enrichment in extracellular matrix
(ECM)-receptor interactions, suggesting that ADP-ribosylation
of this ECM interaction complex might specifically modulate its
function in cell adhesion and ECM-receptor signaling (Figure 1E).
The other interacting protein groups that were identified function
in cell-cell adhesion, calcium ion transmembrane transport, and
vesicular transport (Figure 1E). In summary, these data show that
differentiated muscle cells exhibit ARTC1-dependent NAD+-
inducible ADP-ribosylation responses that mainly affect plasma
membrane and/or extracellular proteins.
ARTC1 Knockout Animals Are Viable and Develop
Normally, but Show Reduced Skeletal Muscle
ADP-Ribosylation and Signs of Muscle Weakness
To elucidate the role of ARTC1 ADP-ribosylation in vivo,
we generated ARTC1-deficient (Artc1/) mice. This was
achieved via insertion of loxP sites into the Artc1 gene (Figures
S3A–S3D). Transgene-positive offspringwerematedwith a dele-
ter strain, which resulted in the generation of Artc1/ knockout
animals. Artc1 gene deletion was confirmed by PCR and ARTC1
protein absence in muscle tissue by western blotting of a glyco-
protein-enriched muscle extract (Figures S3E and 2A). Artc1/
mice were fertile and did not show any overt phenotype. The
overall body constitution as judged by body weight did not
seem to be overtly impaired (Figure 2B). We did observe a slight
reduction in circadian movement, which could be due to muscle
weakness (Figure 2C). Consistently,Artc1/mice showed signs
of muscle weakness in an accelerated rotarod test (Figure 2D),
suggesting that the lack of ARTC1 affects the skeletal or heart
muscle function. Next, we wanted to confirm the importance of
Figure 2. Characterization of the Artc1/
Mouse
(A) Western blotting of glycoprotein-enriched
muscle extracts using an anti-ARTC1 antibody
confirmed the absence of the 39-kDa ARTC1 pro-
tein in Art1c/mice. Two different mice of WT and
Artc1/ genotype were analyzed.
(B) Adult male Artc1/ mice (n = 8) have similar
average weights as their WT littermates (n = 9; bar
graph represents mean and SD).
(C) Monitoring of voluntary activity using the Mouse
E-Motion system. Mice were placed in individual
cages, and movements were recorded in three
consecutive 12-hr light/12-hr dark cycles. Data
points represent the activity of individual mice over
72 hr, expressed as the movement index ± SEM
(Student’s t test).
(D) Endurance of muscle activity was assessed
using the rotarod performance system. Mice were
adapted to the rotarod at low speed (4 rpm) in trials
1 and 2. Trials 3–5 were then performed at an
accelerated speed (8 rpm) with a pause of 45 min
between each trial. Trial 6 was performed the next
day at the accelerated speed. The maximum
duration of mice staying on the rotarod was 5 min. The latency to fall for each group is expressed as mean ± SEM (Student’s t test, *p < 0.05; **p < 0.01).
(E) Primary myoblasts isolated from six littermate pups (genotypes shown at the top), differentiated (D) in vitro into myotubes or undifferentiated (U), were
incubated with [32P]-NAD+ and analyzed by SDS-PAGE and autoradiography (left panel) or Coomassie blue staining (right panel). Position of a prominent
ADP-ribosylated protein is indicated on the left, and molecular weight markers (kDa) are on the right.
See also Figure S3.
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ARTC1 for muscle cell ADP-ribosylation. To this end, primary
myoblasts from wild-type (WT) and Artc1/mice were differen-
tiated in vitro and treated with radioactively labeled NAD+. Auto-
radiograms showed complete absence of surface protein ADP-
ribosylation in Artc1/ myotubes, while WT and heterozygous
cells displayed an Artc1 gene dose-dependent ADP-ribosylation
signal (Figure 2E). Furthermore, the dominant band at100 kDa,
is undetectable in the Artc1/ samples (Figure 2E). A similar ra-
diolabeled band was previously observed in C2C12 myotubes
and was identified as the heavy chain of integrin alpha 7, based
on differential mobility in SDS-PAGE under reducing/non-re-
ducing conditions, binding to a laminin affinity column, co-immu-
noprecipitation with anti-integrin beta 1 antibody, and amino
acid sequencing (Zolkiewska and Moss, 1993, 1995). Together,
these results confirm that ARTC1 is essential in differentiated
muscle cells for ADP-ribosylation of cell surface proteins and
hint at a functional in vivo relevance for ARTC1-mediated ADP-
ribosylation in skeletal and heart muscle.
ARTC1 Is Essential for the Skeletal Muscle ADP-
Ribosylation In Vivo
Having established the Artc1/ mice, we aimed to define the
in vivo ARTC1-dependent ADP-ribosylome of murine skeletal
muscle. Total skeletal muscle protein extracts from unstressed
WT and Artc1/ mice were prepared in a denaturing guani-
dine-HCl lysis buffer, and the ADP-ribosylated fraction was en-
riched and subsequently analyzed by MS as described earlier
(Martello et al., 2016). Importantly, these animals were perfused
with the ARTC inhibitor Novobiocin prior to muscle extraction to
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Figure 3. Profiling of ADP-Ribosylation in
Skeletal Muscle
(A) The ADP-ribosylome of skeletal muscle is
strongly dependent on ARTC1. Venn diagram
of unique identified ADP-ribosylated proteins in
skeletal muscle tissue from WT and Artc1/ mice
(three animals per group).
(B) R-ADP-ribosylation in skeletal muscle tissue
is strongly ARTC1 dependent. Identified ADPr
acceptor sites in WT and Artc1/ skeletal muscle
tissue (n = 3; bar graph represents mean and SD).
(C) Histogram analysis shows that the majority
(78%) of ADP-ribosylated skeletal muscle proteins
carry only one ADPr modification.
(D) Term-enrichment analysis displaying signifi-
cantly enriched (p < 0.001) GO terms of the iden-
tified ADP-ribosylated proteins in WT (n = 573) and
Artc1/ (n = 33) tissue according to their cellular
localization and the biological processes. Term
enrichment is calculated relative to a deep mouse
skeletal muscle proteome (n = 5,647) (Deshmukh
et al., 2015). Numbers in parentheses indicate
participation size and category size, respectively.
See also Figure S3 and Table S2.
inhibit extraction-induced ADP-ribosyla-
tion. MS analyses identified a large basal
ADP-ribosylome in WT animals that con-
sisted of 1,318 unique ADP-ribosylated
peptides (Figure S3F; Table S2), corre-
sponding to 558 ADP-ribosylated proteins (Figure 3A). Good cor-
relations were observed between biological replicates (Fig-
ure S3G). Moreover, a >20-fold reduction in the number of
unique ADPr-peptides in Artc1/muscle tissues was observed,
strongly indicating that ARTC1 is the main writer of skeletal
muscle ADP-ribosylation under basal conditions (Figure S3F).
The importance of ARTC1 for the muscle ADP-ribosylome was
further validated by ADPr-acceptor site specificity analyses. As
expected for ARTC1 targets (Koch-Nolte, 2015), the vast major-
ity of the ADPr-acceptor sites identified in WT tissues were Arg
residues, which were almost completely absent in the corre-
sponding Artc1/ samples (Figure 3B). In fact, the remaining
ADP-ribosylated proteins observed in Artc1/ muscles were
modified on Ser, Lys, Glu, or Asp residues. Over 70% of the
ADP-ribosylated proteins in WT muscle tissues carried only a
single modification (Figure 3C), which suggests that ARTC1-
dependent ADP-ribosylation is a tightly controlled and targeted
process. These findings were further substantiated by GO ana-
lyses, which demonstrated that the identified ADP-ribosylated
proteins localized to extracellular, membrane, and/or mitochon-
drial compartments and function in transmembrane transport,
calcium signaling, and/or ATP metabolic processes (Figure 3D).
ADP-ribosylated proteins from Artc1/ muscle only showed a
significant enrichment in mitochondrial proteins having a role in
ATP-metabolic processes.
Together, these experiments provide evidence that ARTC1
modifies a defined set of proteins already under unstressed con-
ditions and that the observed skeletal muscle ADP-ribosylome
is rather stable. When comparing the ADP-ribosylomes of WT
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Figure 4. Profiling of the Mouse Heart ADP-Ribosylome
(A) The ADP-ribosylome of the heart tissue is strongly dependent on ARTC1. Venn diagram of unique identified ADP-ribosylated proteins in heart muscle tissue
from WT and Artc1/ mice (three animals per group).
(legend continued on next page)
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skeletal muscle and C2C12 myotubes, we found that around
37% of the ADP-ribosylated proteins identified in NAD+-treated
C2C12 myotubes were also modified in the skeletal muscle
(Figure S3H).
The ARTC1-Dependent Heart and Skeletal Muscle
ADP-Ribosylomes Differ
To investigate whether ARTC1 activity or the obtained skeletal
muscle ADP-ribosylome is specific to this tissue or shares simi-
larities with heart tissue, ADP-ribosylome analyses were per-
formed onmouse hearts fromWT and Artc1/mice. Compared
to the skeletal muscle, less ADP-ribosylation sites were identi-
fied in WT hearts under basal conditions; however, Arg was still
the most abundant ADP-ribosylation site and was strongly
reduced in the corresponding Artc1/ tissues (Figures 4A, 4B,
and S4A; Table S3). Around 85% of the observed ADP-ribosyla-
tion sites were dependent on ARTC1 (Figure S4A). The per-
formed MS analyses were reproducible with 70% and 60% of
the ADP-ribosylated proteins identified in at least two biological
replicates for the WT and the Artc1/ tissue samples, respec-
tively (Figure S4B). The variation in the measurement of non-
ARTC1-mediated targets was substantially larger than of
ARTC1 targets. Closer analyses of the ADP-ribosylation sites re-
vealed preferential modification of Arg residues in WT heart tis-
sues only, while Ser, Lys, Glu, or Asp residues were the only sites
identified in Artc1/ hearts (Figure 4B). Similar to what was
observed in skeletal muscle (Figure 3C), approximately 70% of
the modified proteins that were identified in mouse hearts were
ADP-ribosylated at only one site (Figure 4C).
To characterize the mouse heart ADP-ribosylome in more
detail, the ADP-ribosylome data were subjected to GO analysis,
which produced a pattern of term enrichment similar to what
was observed for skeletal muscle. WT heart samples were en-
riched for proteins that localize to the plasma membrane and/
or extracellular space, function in receptor binding and/or trans-
porter activity, and are involved in the regulation of muscle
contraction and apoptotic processes. In contrast, these terms
were absent from the ADP-ribosylomes identified in the
Artc1/ samples, which only showed enrichment for mitochon-
drial proteins and proteins involved in the trichloroacetic acid
(TCA) cycle and ATP synthesis (Figure 4D). This suggests that
ARTC1 most probably manifests its functionality by ADP-ribo-
sylation of a broad array of membrane-associated and extracel-
lular protein targets. To analyze whether specific protein com-
plexes would be ADP-ribosylated and whether the modified
proteins functionally co-regulate certain cellular processes,
STRING-based protein-protein interaction analyses were
carried out for ADP-ribosylated proteins identified either exclu-
sively in WT (Figure 4E) or Artc1/ animals (i.e., ARTC1-inde-
pendent targets; Figure S4C). Nine high-confidence interaction
networks of ADP-ribosylated proteins were identified exclu-
sively in the WT heart muscle samples (Figure 4E). These inter-
action networks mostly contained extracellular and plasma
membrane proteins that are involved in stress responses.
Similar to the C2C12 cells, we found an interaction network of
ADP-ribosylated proteins that mediates ECM-receptor interac-
tions but also identified heart-specific functional interaction net-
works. Interestingly, we identified an ADP-ribosylated protein
network that plays a role in oxidative phosphorylation and is
situated in the mitochondria; however, these proteins were
not modified at Arg and therefore unlikely ARTC1 targets. In
fact, this network fits better to the pattern observed in the
Artc1/ animals. There we identified three ARTC1-indepen-
dent ADP-ribosylated protein networks for mostly mitochondrial
and some cytosolic proteins that function in oxidative phos-
phorylation, TCA cycle, and fatty acid degradation (Figure S4C).
Although we started our analyses with the same amount of
protein (i.e., from heart and skeletal muscle) and observed quite
a large overlap (60%) of ADP-ribosylated proteins identified in
the heart compared to the skeletal muscle tissues (compare Fig-
ure 3A to Figure 4A and Figure S4D), four times more ADP-ribo-
sylated proteins were identified in skeletal compared to heart
muscle tissues. To test our sample-handling regime that was
focused on eliminating ADP-ribosylation reactions due to tissue
extraction and sample preparation, we tested lysis of the tissue
under different conditions (Figure S4E). The lysis was performed
either with a modified RIPA buffer (Larsen et al., 2017) or a
denaturing 6 M guanidine-HCl buffer (Poulsen et al., 2013) in
combination with Novobiocin perfusion, as already performed
previously with the skeletal muscle samples. In addition, animals
were pretreated with Novobiocin (intravenous [i.v.], 30 min
before sacrifice). MS analysis of these three samples revealed
that guanidine-HCl lysis buffer prevented lysis-induced ADP-
ribosylation since pretreatment with Novobiocin i.v. did not
reduce the observed amount of modification. On the other
hand, modified RIPA buffer alone was not able to prevent
lysis-induced ADP-ribosylation, which resulted in an increased
number of identified ADP-ribosylated peptides (compared to
(B) R-ADP-ribosylation in heart tissue is strongly ARTC1 dependent. Identified ADPr acceptor sites in WT and Artc1/ heart tissue (n = 3; bar graph represents
mean and SD).
(C) Histogram analysis shows that the majority (71%) of ADP-ribosylated heart proteins carry only one ADPr modification.
(D) GO term-enrichment analysis displaying significantly enriched (p < 0.001) GO terms of the identified ADP-ribosylated proteins in WT (n = 131) and Artc1/
(n = 26) tissues according to their cellular localization, molecular function, and the biological processes. Term enrichment is calculated relative to a deep mouse
heart proteome (n = 3,157) (Lau et al., 2016). Numbers in parentheses indicate participation size and category size, respectively.
(E) STRING database analysis of high-confidence interaction (interaction score, >0.7) between identified ADP-ribosylated proteins in heart tissue, dependent on
ARTC1 expression. Only ADP-ribosylated proteins with at least one interaction with another ADP-ribosylated protein are shown. Subcellular localization and
biological process are annotated.
(F) Principal-component analysis of the abundance of ADP-ribosylated peptides from WT and Artc1/ hearts that were NAD+ treated or left untreated (three
animals per group).
(G) Volcano plot analysis of WT heart untreated versus NAD+ treated. Significantly different sites are shown in black (FDR < 0.5) and ADP-ribosylation sites are
annotated.
See also Figures S4–S6 and S10 and Table S3.
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guanidine-HCl) consistent with our previous findings for
ARTC2.2 (Bannas et al., 2005) (Figure S4E).
The reduced ADP-ribosylation in the heart could also be due to
different plasma membrane compositions (i.e., affecting ARTC1
complex formation) in heart and muscle, which might affect
ARTC1 activity and affinity to NAD+, or due to overall less
NAD+ in the heart tissue. To test whether the lower amount of
ADP-ribosylation is due to lack of substrate in healthy unstressed
mouse hearts, animals were pretreated with NAD+ (i.v.) 30 min
before sacrifice, the hearts were harvested, and ADP-ribosylome
MS analysis was performed. Injection of NAD+ did not increase
the overall number of identified ADP-ribosylated peptides signif-
icantly, neither in WT nor in Artc1/ background (Figure S5A).
Moreover, NAD+ pretreatment altered neither the ADPr acceptor
site profile nor the number of unique ADPr acceptor sites signif-
icantly (Figure S5B). To strengthen this aspect, we aimed at de-
tecting potential quantitative changes of ADP-ribosylation after
NAD+ treatment by applying a label-free MS1 quantification
approach. Replicate comparison of the signal intensities of
ADP-ribosylated peptides revealed a very strong Pearson corre-
lation among the triplicates of untreated and NAD+-treated WT
tissues (>0.92) and a lower but acceptable correlation among
the Artc1/ replicates (>0.73), respectively (Figure S5C). Prin-
cipal-component analyses of ADP-ribosylated peptide abun-
dance revealed that the ADP-ribosylomes of untreated and
NAD+-pre-treated WT hearts differed and segregated in two
groups, whereas the Artc1/ heart samples were much more
variable and NAD+ treatment did not seem to induce distinct
changes, indicating that when ARTC1 was absent, the NAD+
treatment did not have an effect on ADP-ribosylation (Figure 4F).
Quantitative MS analysis of three independent samples
confirmed that NAD+ treatment of WT mice induces only little
de novo protein ADP-ribosylation but leads to quantitative
changes of discrete ADP-ribosylation sites, most of them already
present in untreated hearts (Figures 4G and S5D). Interestingly,
after applying statistical cutoffs, this analysis showed that
12 ADP-ribosylation sites were significantly more abundant after
the NAD+ treatment, including sites on integrin alpha 7 and HPX,
and that five ADP-ribosylation sites were less abundant after
the treatment, including ADP-ribosylation on ARTC1 itself (Fig-
ure 4G). The NAD+ treatment only changed the degree of the
ADP-ribosylation at specific sites of these proteins; however, to-
tal protein level remained constant for the oneswe could quantify
by label-free quantification (LFQ) of the total proteome before
enrichment (Figure S6A). Integrin alpha 7, which has been shown
before in vitro to be a target of ARTC1, shows the most signifi-
cantly induced ADP-ribosylation (on Arg896 and Arg608) after
NAD+ treatment, which is in line with our results from NAD+-
treated myotubes. Also, integrin alpha 7 interacting ECM pro-
teins LAMB2 showed a significant increase of ADP-ribosylation
at two sites (Arg103 and Arg1458). Moreover, a significantly
increased proportion of ADP-ribosylation on the two soluble
extracellular proteins HPX and Fibronectin1 (FN1) could be
detected upon NAD+ treatment (Figure 4G). In contrast, ARTC1
itself, ARTC3, GPC1, NECTIN2, CSPG4, and EFNB3, all of
them plasma membrane proteins, were less abundantly modi-
fied after NAD+ treatment. The reduction inmodification on these
proteins could be due to shedding by metalloproteases, which
would sequester them from the membrane-bound ARTC1 (Bu-
chanan et al., 2017; Janes et al., 2009; Kawahara et al., 2017;
Menzel et al., 2015; Sakry et al., 2014).
Apart from ARTC1, we also found ARTC3 to be ADP-ribosy-
lated in WT skeletal and heart muscle tissue, but not in Artc1/
tissue. This indicates that ARTC3 is ADP-ribosylated by ARTC1,
especially since no significant changes in total ARTC3 protein
levels could be observed in the different WT and Artc1/ tissue
samples (Figure S6B).
Arginine ADP-Ribosylation Motifs and Marker Ion
We attempted to identify an Arg-ADP-ribosylation consensus
motif as previously identified for nuclear Ser-ADP-ribosyla-
tion (Bilan et al., 2017a; Bonfiglio et al., 2017). Analysis of
a 21-aa window with the identified Arg-ADP-ribosylation
sites in the middle revealed five significantly enriched motifs
(p < 0.0005, binomial test), comprising 78%, 30%, and 63%
of all identified Arg-ADP-ribosylation sites in C2C12, skeletal
muscle, and heart muscle, respectively (Figure 5). The most
prominent motif identified consisted in an R(-ADPr)G motif (in
all sample types), followed by an RR(-ADPr) motif (in skeletal
and heart muscle).
We noticed that a large portion of ADP-ribosylated peptides
contain missed cleavage sites. In the case of our skeletal muscle
dataset, we found that 70% contained one missed cleavage
site, whereas 60% of non-modified peptides showed no
missed cleavage (Figure S7A). Most missed cleavage sites
include ADP-ribosylated arginine residues, with the likely expla-
nation of sterical hindrance of trypsin binding. In contrast to un-
modified peptides, we identified a large proportion of missed
cleavage site with arginines at the first position of ADP-ribosy-
lated peptides, 25% in skeletal muscle (Figure S7B). These
arginines were almost exclusively identified as ADP-ribosylation
sites and mainly belonged to the RR(-ADPr) motif identified
above. This suggests that trypsin is able to recognize and cleave
after an arginine or lysine preceding a modified arginine residue;
however, it is not able to process the modified residue itself. This
has been observed for serine ADP-ribosylation as well (Bonfiglio
et al., 2017). To further validate the presence of modified argi-
nines at the first position of the peptides, we performed a
small-scale Lys-C protease (cleaves only after lysine) and trypsin
digest on the same skeletal muscle sample. Interestingly, in
contrast to the tryptic digest, Lys-C digestion resulted for both,
non-modified and ADP-ribosylated peptides, in less than 5%
missed cleavage sites (Figure S7C), indicating that arginine
ADP-ribosylation blocks trypsin recognition of the modified
amino acid but exhibits less hindrance of protease processing
of adjacent or close-by sites. ADP-ribosylated peptides derived
from Lys-C digestion suffered generally from lower ADP-ribosy-
lation site localization probabilities compared to tryptic ADP-
ribosylated peptides (Figure S7D). The data generated by the
Lys-C experiment was not extensive enough to predict statisti-
cally relevant ADP-ribosylation motifs. However, we were still
able to validate identified RR(ADPr) sites in Lys-C-derived pep-
tides (Figure S8A) and could prove that these sites can indeed
exist as tryptic peptides with a missed cleaved and modified
arginine in the first position (Figure S8B) or as Lys-C peptides
with an internal ADP-ribosylation site (Figures S8C and S9).
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Studies of in vitro-modified peptides have suggested that
ADP-ribosylated Arg residues can give rise to an Arg-specific
ADPr marker ion (ADPr-carbodiimide; Figure S10A) during MS2
fragmentation (Osago et al., 2009).
Due to the unusual elemental composition of ADPr-carbodii-
mide, which contains two phosphate groups, its accurate m/z
value (584.09019) can easily be distinguished from any peptide
fragment ion by using Orbitrap mass analyzers. ADPr marker
ions can be extracted from MS2 spectra and have proven bene-
ficial in the identification and validation of ADP-ribosylated pep-
tides (Bilan et al., 2017a). We screened MS2 spectra from the
measured heart samples using the PTM marker finder R-pack-
age to extract ADPr marker ions (Nanni et al., 2013; Panse and
Grossmann, 2012). When we screened for spectra containing
at least four ADPr marker ions, we could identify 361 spectra
containing an ADPr-carbodiimide ion (10% of spectra) in the
WT samples and only 3 in Artc1/ samples (0.9% of spectra)
(Figure S10B). As expected, ADPr-carbodiimide ions showed a
lower intensity than the other marker ions; however, in many
cases they were readily identified and could be used to estimate
the Arg-specific ADP-ribosylation levels (Figures S10B and
S10C).
ADP-Ribosylation of HPX Reduces Its Capacity to Bind
Heme
To validate our findings, we investigated the functional relevance
of HPX ADP-ribosylation, which was identified on Arg-218 in
heart and skeletal muscle tissue. HPX is the strongest known
heme binder (Tolosano and Altruda, 2002) and plays a crucial
role during inflammatory conditions by scavenging heme (Tolo-
sano and Altruda, 2002). To confirm that HPX is a direct
ARTC1 target, recombinant HPX was incubated with ARTC1
and radiolabeled NAD+. We found that recombinant ARTC1
modified HPX in vitro and that no glycation or passive attach-
ment of NAD+ to HPX occurs (Figure 6A). ARTC1-dependent
HPX modification was sensitive to ARTC inhibitor Novobiocin
and slightly decreased in the presence of heme (Figure 6B).
MS analysis of the in vitro reaction confirmed the ADP-ribosyla-
tion of Arg218 in vitro and additionally identified ADP-ribosyla-
tion on R83. Manual annotation of higher-energy collision disso-
ciation (HCD) and electron-transfer/higher-energy collision
dissociation (EThcD) fragmentation spectra for in vivo- and
in vitro-modified HPX peptides confirmed ADP-ribosylation on
Arg218 and revealed Arg-ADP-ribosylation-specific ADPr-car-
bodiimide ions and losses of the corresponding neutral frag-
ments (Figure 6C). Arg218 faces the heme binding pocket of
HPX and might therefore interfere with heme binding upon
ADP-ribosylation (Figure 6D). To test this possibility, a heme
binding assay measuring the HPX-heme protein complex forma-
tion absorbance at 413 nm was established (Hvidberg et al.,
2005). ADP-ribosylated HPX was strongly impaired in its heme
binding capacity as compared to unmodified HPX (Figures 6E
and 6F), indeed suggesting that the ADP-ribosylation of HPX
might regulate its heme binding capacity and might therefore
be a physiologically relevant function.
DISCUSSION
In this study, we investigated the targets of ARTC1 in C2C12 my-
otubes, as well as in skeletal and heart muscle tissues at the sys-
tems level. These proteome-profiling studies, which compared
tissues fromWTandArtc1/mice, uncovered a large, previously
unidentified ARTC1-dependent ADP-ribosylome composed of
mainly membrane and secreted proteins that were most often
modified on a single Arg. Ser, Lys, Glu, and Asp modifications
were also identified, but these ADP-ribosylation events were not
dependent on ARTC1.We showed that Arg-specific ADP-ribosy-
lation could be additionally confirmed using a diagnostic ADPr-
carbodiimide ion specific for the modified Arg for 10% of the
Arg-ADPr-peptide spectra. Comparisonof the identified peptides
revealed sequence motifs with enriched Gly and Arg adjacent to
the modified Arg within ARTC1 target proteins.
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Figure 5. Arginine ADP-Ribosylation Motifs
R/G and R/Rmotifs identified at Arg-ADP-ribosylation sites with a localization probability of >90% in C2C12 cells, WTmuscle, and heart tissue compared against
the whole mouse proteome as background (binomial test, p < 0.0005) using x-motif (Chou and Schwartz, 2011). Percentage of all Arg-ADP-ribosylation sites
containing the motif and motif score are shown on top of the respective sequence motif.
See also Figures S7–S10.
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Based on the vast amount of proteins identified under un-
treated conditions in vivo, ARTC1 seems to be constitutively
active and to play a role under steady-state conditions, which
is in stark contrast to the intracellular stress-responsive
ARTD1–3. The very strong drop in the number of detectable
ADP-ribosylation sites in Artc1/ compared to WT mice
strongly suggests that ARTC1 is the main contributor to the skel-
etal and heart ADP-ribosylome under untreated conditions (Fig-
ures 2 and 3). ARTC2.2 was not expressed in C2C12 or the
tested tissues. ARTC3 is expressed in C2C12 cells; however, it
CA
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B
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Figure 6. ARTC1-Mediated ADP-Ribosylation of HPX Interferes with Heme Binding
(A) Autoradiography of mouse hemopexin (HPX) in vitro ADP-ribosylation by recombinant mouse ARTC1 or NAD+ alone. Heme (10 mM) was added to indicated
reactions.
(B) Autoradiography of mouse HPX in vitro ADP-ribosylation by recombinant mouse ARTC1. Heme (10 mM) or Novobiocin (10 mM) were added to indicated
reactions.
(C) Manual annotation of high-resolution HCD (top) and EThcD (bottom) MS2 fragmentation spectrum of a HPX peptide confirms ADP-ribosylation on R218.
Spectra were retrieved frommeasuredWT heart tissue and in vitromodified HPX, respectively. The y and z ion series are shown in green, the b and c ion series are
in blue, and the ADPr-specific marker ions and neutral losses are indicated in red.
(D) Crystal structure of HPX bound to heme (red) (Paoli et al., 1999) with indicated ADP-ribosylation sites. The ADPr sites on Arg218 detected in WT heart and
skeletal musclemight interfere with HPX ability to sequester heme due to its very close proximity to the heme-binding site. ADP-ribosylated Arg218 and Arg83 are
highlighted.
(E) Absorbance measurement of non-modified HPX (HPX incubated with NAD+) or ADP-ribosylated HPX (HPX incubated with NAD+ and ARTC1) incubated in
the presence of different concentrations of heme. Average absorbance measurement from 300 to 600 nm for the different reactions in triplicates are shown; the
HPX-heme complex absorbs light at 413 nm.
(F) ARTC1-mediated ADP-ribosylation of HPX inhibits heme binding in vitro. Binding was assessed as in (E) and OD413 is shown as a bar plot for triplicate
measurement of the indicated reactions (n = 3; bar graph represents mean and SD, t test, **p < 0.01).
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did not show any detectable catalytic activity. Furthermore,
expression of ARTC3 is independent of ARTC1 expression and
it does not contribute to the ADP-ribosylome. Nevertheless,
ARTC3 was detected as an ADP-ribosylated protein in WT skel-
etal and heart muscle tissue, but not in the Artc1/ tissue. On
the basis of these findings, we propose that ARTC3 is modified
by ARTC1, even though we cannot rule out the possibility that
ARTC3 shows weak automodification activity.
NAD+ can be released upon necrosis or mechanical stress in
tissue, which could activate ARTCs during organ collecting
(Koch-Nolte et al., 2011). Considering that ARTCs have higher
affinity for NAD+ compared to intracellular ARTDs, ARTCs are
more prone to activation following NAD+ release during tissue
collecting (Koch-Nolte et al., 2011). The ADP-ribosylomes we
profiled were quite stable and constrained to the extracellular
compartment, the plasmamembrane, the ER, and themitochon-
dria with modification of many low-abundant proteins. STRING
analysis identified modification of multiple interacting proteins
involved in ECM-receptor interaction, cell adhesion, and trans-
membrane transport, suggesting that ARTC1 might unfold its
biological potential by targeting whole protein complexes.
Much of the identified intracellular Arg-ADP-ribosylation is
detected in the endomembrane system (as identified by GO
term-enrichment analysis) and likely corresponds to protein
modification occurring during maturation (ER and Golgi) as
both ARTC1 and its target proteins are processed in and traffic
through these compartments. The mitochondrial proteins might
be ADP-ribosylated non-enzymatically due to the high NAD+
concentration in the mitochondria (Koch-Nolte et al., 2011) or
by an unknown mitochondrial ART. Alternatively, the finding of
some cytoplasmic and mitochondrial Arg-ADP-ribosylated pro-
teins could mean that the applied extraction procedure might
in some cases still lead to ADP-ribosylation of intracellular pro-
teins due to tissue damage induced upon excising the tissues,
as previously reported for ARTC2.2 (Bannas et al., 2005). It will
be interesting to test whether ARTC1-mediated ADP-ribosyla-
tion also has a function in endogenously occurring tissue
damage.
The remarkable stability of the observed ARTC1-mediated
ADP-ribosylomes contrasts with the induced ADP-ribosylomes
catalyzed by ARTD1 upon oxidative stress, which can be de-
tected only for a few minutes (Martello et al., 2016). Reversibility
of cell surface ADP-ribosylation was previously studied on integ-
rin alpha 7 revealing that surface ADP-ribosylation is not readily
reversed by ADP-ribosylhydrolases (Zolkiewska and Moss,
1995). These findings suggested that the responsible erasers
operate outside the postulated ADP-ribosylation cycle. ARH1,
the only known arginine-specific ADP-ribosylhydrolase, is solely
expressed within the cell, but not secreted. It is thus tempting to
speculate that the extracellular ADP-ribosylation could only be
removed from the cell membrane proteins by internalization
and protein degradation or shedding, potentially rendering the
removal of Arg-ADP-ribosylation a slow process. Alternatively,
ADPr could also be processed by extracellular phosphodiester-
ases, thereby converting it to phospho-ribosylated proteins.
Comparison of ADP-ribosylated proteins in the three sample
types revealed a 40% overlap between the C2C12 sample and
the in vivo samples and a 44% overlap between the two in vivo
muscle sample types. Although the proteome of C2C12 is
different from skeletal muscle (44% of the proteins show a
different expression profile [Deshmukh et al., 2015]), this does
not explain the limited overlap of the ADP-ribosylomes but rather
suggests that ARTC1’s expression levels, activity, and speci-
ficity are different in cell culture compared to in vivo. These differ-
ences could stem from variations in the ECM and local fluids that
control ARTC1 activity. In analogy to ARTC2, it is possible that
the targets of ARTC1 are also restricted to raft-associated
target proteins (Bannas et al., 2005). Alternatively, differential
concentrations of available NAD+ could lead to a different
ADP-ribosylome.
Computational analysis of all modified peptide sequences re-
vealed motifs for many Arg-ADP-ribosylation sites and showed
that often another Arg or a Gly residue is positioned adjacent to
a modified Arg (Figure 5). The Arg/Arg motif might provide a
beneficial environment for the catalytic ART process or might
serve as a positively charged protein-protein interaction patch
whose functionality could be annihilated by ADP-ribosylation
of one of the arginines. A Arg/Arg motif was already observed
for individual proteins in in vitro ARTC2.2 assays (Adriouch
et al., 2008). Interestingly, the Ser modified by ARTD was also
found to be adjacent to a positively charged Lys or Arg residue
(Bilan et al., 2017a), suggesting that a positively charged amino
acid beside the ADPr acceptor site might be important for the
biochemical reaction independent whether the modification is
catalyzed by ARTC or ARTD family members. The Gly/Arg
and Arg/Gly motifs might render the Arg more accessible to
ARTC1.
The identification of the Arg-specific ADPr-carbodiimide
marker ion for a subset of Arg-ADP-ribosylated peptides in com-
plex samples opens the possibility to include the marker ion in
product-dependent MSmethods upon optimizing fragmentation
energies (Bilan et al., 2017a; Leidecker et al., 2016; Osago et al.,
2009; Rosenthal and Hottiger, 2014). This will be beneficial while
studying ARTC targets in complex backgrounds by specifically
targeting Arg-ADP-ribosylated peptides and thereby acquiring
high-quality spectra.
In ARTC1/ samples, also a residual ARTC1-independent
ADP-ribosylome could be detected, which was not affected by
NAD+ pretreatment. Our data reveal that these proteins were
mainly modified at Ser, Lys, Glu, or Asp. However, these sites
were by far less abundant than the identified ARTC1 targets.
Compared to the arginine-modified sites, it was difficult to
obtain good localization for these alternative modification sites,
probably due to their labile ADPr-peptide bond upon MS2 frag-
mentation (Bonfiglio et al., 2017). These proteins with ARTC1–in-
dependent ADP-ribosylation were identified by term enrichment
analysis to be involved in metabolic processes and oxidative-
reduction processes, and mainly localized to the mitochondria,
suggesting that these processes may be influenced by the
modification. As mentioned above, the high NAD+ concentration
found in mitochondria might also favor non-enzymatic ADP-
ribosylation for these proteins (Koch-Nolte et al., 2011). NAD+
i.v. injection (i.e., a DAMP signal) did not markedly alter the total
number of ADP-ribosylated sites of the analyzed heart tissues,
but changed their quantitative composition. It is likely that
NAD+ treatment induces a metalloprotease (e.g, ADAM17)
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(Menzel et al., 2015), which would lead to shedding of plasma
membrane proteins. Indeed, GPC1 as well as NECTIN4, the
close relative of NECTIN2, are known to be shed by ADAM17
(Buchanan et al., 2017; Kawahara et al., 2017). CSPG4 and
EFNB3 can be cleaved by ADAM10, the close relative of
ADAM17 (Buchanan et al., 2017; Janes et al., 2009; Sakry
et al., 2014) The soluble form of these proteins might be less effi-
ciently targeted by membrane-bound ARTC1. ARTC2.2, the
close relative of ARTC1 and 3, has been shown to be released
by ADAM17 (Menzel et al., 2015). Interestingly, the region close
to the GPI-anchor where ARTC2.2 is cleaved is conserved in
GPI-anchored ARTC1 as well as in ARTC3, indicating that they
might also be shed (Menzel et al., 2015). Release of ARTC1 itself
might lead to a shift in its activity toward soluble proteins such as
HPX and FN1 as shown previously for ARTC2.2 (Menzel et al.,
2015). So far, it is not clear which targets are modified by soluble
ARTC2.2.
Moreover, we characterized and functionally validated the
ADP-ribosylation of HPX using purified recombinant proteins
and observed that in vitro modification of HPX strongly inter-
fered with its capacity to bind heme (Figure 6). HPX is a soluble
protein that it is usually found in heart and skeletal muscle tis-
sue (Deshmukh et al., 2015; Lau et al., 2016). After acute hemo-
lysis (e.g., after post-ischemic reperfusion or sepsis), excess
heme is bound by HPX (Fasano et al., 2005). HPX-heme com-
plexes are taken up by macrophages or hepatocytes and
heme is degraded (Hvidberg et al., 2005). HPX is also important
for heme export from cells, by accepting heme from export pro-
teins, indicating that HPX also has a function directly at the
plasma membrane, placing it in the potential vicinity of
ARTC1 (Yang et al., 2010). The inhibitory role of ARTC1-medi-
ated ADP-ribosylation might thus play a role in heme homeo-
stasis by shifting the binding of heme to other proteins and
reduce heme degradation under non-stressed conditions. Inter-
estingly, a recent report provides evidence that post-transla-
tional oxidative modification of HPX’s Tyr199, which is in close
structural proximity to R218, also impairs heme binding (Hahl
et al., 2017).
The identified ARTC1 target proteins seem to be involved
in various pathways controlling muscle function, which might
explain the observed reduced endurance of the muscle activity
in Artc1/ mice. Whether this observation is only due to
skeletal, heart, or both muscle tissues needs to be further
addressed. ARTC1 is GPI-anchored and seems to be concen-
trated in lipid rafts at the cell surface. This topology could regu-
late ARTC1’s specificity to other membrane proteins associated
with lipid rafts (Seman et al., 2004). The STRING analyses sur-
prisingly identified a modified protein network in the mitochon-
dria in WT tissue, which was not detected in Artc1/ tissue. We
found that these mitochondrial ADP-ribosylation sites are lower
abundant than the extracellular ARTC1 targets, making them
more prone to biological as well as sample and measurement
variations.
Together, we identified and compared the ADP-ribosylomes
of the murine skeletal muscle and heart tissue, and we showed
that they are largely ARTC1 dependent. Furthermore, our sys-
tem-level analyses show that, in vivo, ARTC1 has an immense
target space, which is remarkably stable. We provide a rich
resource for ARTC-mediated ADP-ribosylation research, which
was so far limited to a few targets and cumbersome
biochemical identification of sites by site-directed mutations
and in vitro experiments. The ADPr-acceptor site localiza-
tion database that we provide here contains HCD and
EThcD ADPr spectra resource of primary tissue (data are
available via ProteomeXchange with identifier PXD008041)
and can be used by researchers as a resource to further inves-
tigate the functional implication of ADP-ribosylation in muscle
tissues.
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AF1521 protein, recombinant Martello et al., 2016 N/A
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DC27.10 lymphoma cells overexpressing
FLAG-tagged mouse ARTC1 or mouse ARTC3
Koch-Nolte et al., 2005 N/A
Experimental Models: Organisms/Strains
C57BL/6 ARTC1/ This study N/A
Software and Algorithms
Proteome Discoverer, v2.1 Thermo Fisher Scientific Cat# OPTON-30812
Mascot 2.5.1.3 matrixscience http://www.matrixscience.com
Progenesis QI v. 3.0.6039.34628 Nonlinear dynamics http://www.nonlinear.com
Scaffold v.4.7.2 Proteome software http://www.proteomesoftware.com
Perseus software suite Max Planck Institute of Biochemistry,
Department of Proteomics and Signal
Transduction, Munich
http://www.biochem.mpg.de/5111810/
perseus
GOrilla Eden et al., 2009 http://cbl-gorilla.cs.technion.ac.il
STRING v. 10.5 Szklarczyk et al., 2015 https://string-db.org/cgi/input.pl
PANTHER Mi et al., 2017 http://pantherdb.org
PTM marker finder Nanni et al., 2013 N/A
motif-x Chou and Schwartz, 2011 http://motif-x.med.harvard.edu
Perseus software suite Max Planck Institute of Biochemistry,
Department of Proteomics and Signal
Transduction, Munich
http://www.biochem.mpg.de/5111810/
perseus
Other
Orbitrap Fusion Tribrid mass spectrometer Thermo Fisher Scientific Cat# IQLAAEGAAPFADBMBCX
Orbitrap Q Exactive HF mass spectrometer Thermo Fisher Scientific Cat# IQLAAEGAAPFALGMBFZ
nano EasyLC 1000 Thermo Fisher Scientific Cat# LC120
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests should be directed to and will be fulfilled by the Lead Contact, Michael O. Hottiger (michael.
hottiger@dmmd.uzh.ch). For some items such as ARTC1-deficient mice MTAs may apply.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Generation and Characterization of Artc1/ Mice
All chemicals were purchased from Sigma unless otherwise stated. Mice were obtained from the Animal Resources Units of the
University of California at San Francisco and the University Medical Center, Hamburg. Experiments were performed in accordance
with international guidelines on the ethical use of animals and were approved by the lcoal animal welfare commission (Amt f€ur
Verbraucherschutz, Lebensmittelsicherheit und Veterina¨rwesen Hamburg, Nr. 12/130). A targeting vector for the Artc1 locus was
constructed in which loxP sites were introduced up- and downstream of the Artc1-encoding exons 3 and 4 and a pgk-neomycin
resistance cassette. The targeting construct was linearized with NotI and transfected into RF8 ES cells. Neomycin resistant clones
were screened by Southern Blot analyses using informative 50 and 30 flanking probes. Two of 600 tested clones showed additional
bands indicating homologous recombination at the target locus. Following injection of these ES cells into B6 blastocysts, chimeric
male and female mice were obtained. Germline transmission of the targeted locus was obtained for both clones upon mating of
chimeric and B6 mice. PCR analyses using primers flanking the distal loxP site confirmed the presence and Mendelian inheritance
of this site. Artc1 floxed mice were mated with mice expressing the cre recombinase under control of the b-actin promoter (deleter
mice). PCR analyses using primers from the neomycin gene and the 30 flanking region of the Artc1 gene yielded a diagnostic band in
progeny but not parental mice, indicating deletion of exons 3 and 4 in the targeted Artc1 allele. Artc1/mice were backcrossed onto
the C57BL/6 background for 12 generations.
Performance Assessment
Sex and age matched adult WT and Artc1/mice were monitored for voluntary activity using the Mouse E-Motion universal mobile
datalogger system (INFRA-E-MOTION GmbH, Hamburg, Germany). Mice were placed in individual cages and movements were re-
corded in three consecutive 12 h light/12 h dark cycles. Endurance of muscle activity was assessed using the rotarod performance
system (TSE systems, BadHomburg, Germany). For this,micewere adapted to the rotarod at low speed (4 rpm) in trials 1 and 2. Trials
3-5 were then performed at an accelerated speed (8 rpm) with a pause of 45 min between each trial. Trial 6 was performed the next
day at the accelerated speed. The maximum duration of mice on the rotarod was 5 min. Experiments were performed in accordance
with international guidelines on the ethical use of animals and were approved by the local animal welfare commission (Amt f€ur
Verbraucherschutz, Lebensmittelsicherheit und Veterina¨rwesen Hamburg, Nr. 12/130).
Mouse Treatment and Organ Harvesting for Proteomic Experiment
WT and ARTC1/ C57BL/6 mice were maintained on a 12-h light-dark cycle with regular unrestricted diet. WT (male, 15weeks) and
ARTC1/ (male, 9 weeks) micewere injectedwith 10mgNAD+ or stayed untreated and sacrificed after 30min. Mice (n = 3 per group)
were anesthetized with isoflurane and perfused with PBS containing 1 mM Novobiocin. Heart and skeletal muscle from legs were
collected and immediately snap-frozen in liquid nitrogen. All samples were stored at 80C. In order to optimize the analysis and
to rule out ADP-ribosylation artifacts induced by stress and lysis, we evaluated different sample preparation methods and decided
for a strongly denaturing Gnd-HCl lysis protocol and in vivo perfusion with the ARTC inhibitor Novobiocin. An additional Novobiocin
treatment 30 min before euthanasia of the animals did not lead to further reduction in the ARTC1-dependent ADP-ribosylome
and was thus judged to be unnecessary (Figure S4E). For untreated organ donors, untreated WT and ARTC1/ C57BL/6 were
maintained on a 12-h light-dark cycle with regular unrestricted diet. Organs of untreated animals were taken under license
ZH207/2015 according to institutional and cantonal regulations.
Cell Culture and Treatments
The mouse skeletal muscle cell line C2C12 was maintained below 60% confluence in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 20% fetal calf serum and 1x penicillin/streptomycin (Invitrogen). For differentiation into myotubes, cells were
grown until complete confluence and, subsequently, growth medium was exchanged for DMEM supplemented with 0.5% fetal
calf serum and 1x penicillin/streptomycin (Invitrogen). This differentiation medium was exchanged every 24h until day 4 of differen-
tiation. For transient knockdown of ARTC1 or ARTC3, about 1 million C2C12 cells were seeded per 6 cm dish and transfected with
siRNA against either ARTC1, ARTC3 or a scrambled siRNA using lipofectamine RNAiMAX (Invitrogen) according to the manufac-
turer’s manual. For the NAD+ treatment, differentiated myotubes were washed twice with serum free DMEM and subsequently treat-
ment was performed for 30 min in serum free DMEM containing either 1 or 50 mM NAD+.
Wild-type DC27.10 lymphoma cells (Koch-Nolte et al., 2005), as well as DC27.10 cells overexpressing either FLAG-tagged
mARTC1 or mARTC3 were cultured in RPMI medium supplemented with 10% FCS and 1x penicillin/streptomycin (Invitrogen).
Primary myoblasts were isolated from hindlimbs and forelimbs of neonatal mice (2-5 days old). Themuscle tissue was incubated in
Dulbecco’s phosphate-buffered saline (DPBS) with 1% collagenase II (Invitrogen), 2.4U/ml dispase II (Roche) and 2.5 mM CaCl2 for
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45 min at 37C, and then passed through 100 mm-nylon mesh filter (BD Biosciences). The filtrate was centrifuged, the cell pellet was
suspended in Ham’s F-10medium (Cambrex) containing 20%FBS and 1%penicillin/streptomycin, pre-plated for 30min on collagen
I-coated plates, and then plated on tissue culture-treated plastic plates. To stimulate differentiation of myoblasts to myotubes,
90%–100% confluent myoblasts were incubated for 3 days in medium containing 2% horse serum.
METHOD DETAILS
Gene Expression
RNA extraction was performed with the NucleoSpin RNA II kit (Macherey-Nagel). Mouse tissue samples were lysed using a tissue
lyser II (QIAGEN) with the provided lysis buffer. C2C12 myotubes were washed with PBS, before lysis with the same buffer. After
RNA extraction RNA was quantified with a NanoDrop (Thermo Fisher Scientific) and reverse transcribed according to the supplier’s
protocol (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems). Quantitative real-time polymerase chain reactions
(qPCR) were performed with KAPA SYBR fast (Kapa Biosystems) and a Rotor-Gene Q 2plex HRM System (QIAGEN).
Flow Cytometry
Two million DC27.10 cells per condition (WT, ARTC1/3) were stained with an anti-FLAG antibody (M2, Sigma) diluted 1:750 in PBS
containing 2% BSA for 30 min on ice. Cells were further washed 3 times and stained with a secondary antibody conjugated to A488
(Biolegend) for another 30 min on ice in the dark. After 3 washes, cells were resuspended in 500 ml PBS and analyzed via flow
cytometry using a FACSCanto (BD Biosciences).
Immunoblotting
Three-month old wild-type andArtc1/micewere euthanized byCO2 inhalation in accordancewith a protocol approved by the Kan-
sas State University Institutional Animal Care and Use Committee. Hind limb muscles were excised, ground, and homogenized in
50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 50 mM octylglucoside, 1 mM AEBSF, 5 mg/ml aprotinin, 5 mg/ml leupeptin, 5 mg/ml pepstatin
A (5 mL homogenization buffer/1 g tissue). The homogenate was centrifuged at 13,000 g for 20 min, the supernatant was filtered
through a 0.45 mm filter, and incubated with 0.2 mL of Concanavalin A agarose beads at 4C for 2 h with gentle shaking. The beads
were washed with 5 mL of homogenization buffer and eluted with SDS-PAGE loading buffer, the eluate was resolved by SDS-PAGE
and transferred to a nitrocellulose membrane. The membrane was blocked with 3% (w/v) dry milk and 0.3% (v/v) Tween-20 in DPBS,
then incubated with anti-ARTC1 antibody (Koch-Nolte et al., 2005) in blocking buffer, followed by incubation with horseradish perox-
idase-labeled secondary antibody and detection using the WestPico chemiluminescence kit (Pierce).
ADP-Ribosylation Reaction on Cells
Differentiated primary myoblasts (myotubes) were washed with DPBS and incubated for 30 min in DPBS (with Ca2+ and Mg2+)
containing 5 mM [adenylate-32P] NAD+ and 1 mM ADP-ribose. Cellular proteins were extracted with extraction buffer (50mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1 mM ADP-ribose, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM 4-(2-aminoethyl)-ben-
zene-sulfonylfluoride hydrochloride (AEBSF), 5 mg/ml aprotinin, 5 mg/ml leupeptin, 5 mg/ml pepstatin A, 10 mM 1,10-phenanthroline;
0.5 mL extraction buffer/well in a 6-well plate). Cell extracts were centrifuged at 21,000 g for 15 min, and supernatants were analyzed
by autoradiography after SDS-PAGE under reducing conditions.
C2C12 myotubes pretreated with siRNA against either ARTC1, ARTC3 or a control siRNA were washed twice with serum free
DMEM and subsequently incubated for 30 min with [32P]-NAD+ (2 mCi and 1 mM NAD+/dish) at 37C. After treatment, cells were
washed 3 times with serum free DMEM and membrane proteins were isolated by incubating the cells for 20 min on ice in presence
of 200 ml membrane solubilization buffer (PBS, 1% Triton X-100, Roche Protease Inhibitor, 100 mM Novobiocin and 10 mM PJ34).
Lysed cells were further detached from the plates by scraping and centrifuged for 15 min at 13,000 g to remove insoluble material.
The supernatants were analyzed via autoradiography after SDS-PAGE under denaturing conditions.
Six million DC27.10 cells per condition (WT, ARTC1/3 overexpressing) were incubated in the presence of [32P]-NAD+ and pro-
cessed as described for the C2C12 cells with the exception that, being suspension cells, DC27.10 cells had to be centrifuged
down for each washing step.
ADP-Ribosylation Reaction with Recombinant Proteins
Recombinant mouse ARTC1 was purified from DC27.10 lymphoma cells stably transfected with FLAG-tagged ARTC1 (Koch-Nolte
et al., 2005). DC27.10_ARTC1 cells were incubated with Phospholipase C (Sigma) for 1 h at 37C. Cell supernatants were clarified by
centrifugation (20 min, 13000 g) and ARTC1 was purified by affinity chromatography on agarose immobilized anti-FLAG mAb M2
(Sigma). The column was washed with PBS, 1% Triton X-100 and ARTC1 was eluted with 100 mM glycine, 10 mM Tris (pH 2.7).
The eluate was neutralized with one-tenth volume of 1 M Tris (pH 9.0) and the buffer was exchanged to PBS by gel filtration
(PD-10 columns; Pharmacia). ARTC1 was concentrated using centrifugal filters (Millipore; molecular weight cutoff 10 kDa). Recom-
binant mouse hemopexin was purchased from Sino Biological. To monitor trans ADP-ribosylation of HPX by radiography we
incubated 50 nM ARTC1 with 2.5 mM HPX using 0.5 mCi [32P]-NAD+ (Perkin Elmer) in PBS and incubated at 37C for 30 min or
60 min. For some reactions 10 mM Novobiocin or 10 mM heme was added. Reactions were stopped by adding SDS-loading buffer,
e3 Cell Reports 24, 1916–1929.e1–e5, August 14, 2018
with subsequent boiling at 95C for 5 min. Samples were run on an SDS-PAGE gel, stained with Coomassie blue, photographed,
destained, and exposed on phosphorscreens overnight. Images were taken with a Typhoon FLA 9400 phosphorimager (GE
Healthcare).
For the Heme-HPX binding assay as well as for subsequent MS analysis 10 mM HPX was incubated with 100 mM NAD+ with or
without 250 nM ARTC1 in PBS, overnight at 37C. The next day, indicated amounts of heme were added to the reaction, incubated
at 37C and absorbance was measured with a NanoDrop (Thermo Fisher Scientific) and the OD at 413 nM was quantified for the
different reactions. All reactions were done and measured as independent triplicates.
ADPr-Peptide Enrichment
C2C12 cells were washed twicewith PBS and subsequently lysed and scraped by adding 95CGnd-HCL-lysis buffer (6Mguanidine-
hydrochloride, 5 mM tris(2-carboxyethyl)phosphine (TCEP), 10 mM chloroacetamide (CAA), in 100 mM Tris pH 8). Frozen murine
heart and skeletal muscle samples were added to 95C Gnd-HCL-lysis buffer and ground in a tissue lyser II (QIAGEN), for 3 min
at 30hz. Samples were subsequently incubated at 95C for 10 min and sonicated for 1 min at an amplitude of 30%. Lysate was
cleared by centrifugation at 4000 g, ten times diluted with 25 mM Tris pH 8, and digested with sequencing grade trypsin (Promega).
The peptide mixture was treated with PARG enzyme to reduce potentially PARylated peptide to MARylated peptides, and the
peptides were enriched using an Af1521 macrodomain affinity enrichment and prepared for MS analysis as described previously
(Martello et al., 2016). The in vitromodified HPX protein was processed using filter aided sample preparation (FASP) protocol using
Microcon-30-kDa-cutoff filter units (Millipore) and sequencing grade trypsin (Promega) (Wisniewski et al., 2009).
Liquid Chromatography and Mass Spectrometry Analysis
Identification of ADP-ribosylated peptides from C2C12, skeletal muscle, heart and recombinant HPX was performed on an Orbitrap
Fusion Tribrid mass spectrometer (Thermo Fisher Scientific), coupled to a nano EasyLC 1000 liquid chromatograph (Thermo Fisher
Scientific). We applied an ADP-ribose product-dependent method called HCD-PP-EThcD (Bilan et al., 2017a) Briefly, the method
includes high-energy data-dependent HCD, followed by high-quality HCD and EThcD MS/MS when two or more ADP-ribose frag-
ment peaks (136.0623, 250.0940, 348.07091, and 428.0372) were observed in the HCD scan. A detailed description of the MS
parameters can be found in (Bilan et al., 2017a). Solvent compositions in channels A and B were 0.1% formic acid in H2O and
0.1% formic acid in acetonitrile, respectively. Peptides were loaded onto an Acclaim PepMap 100 (Thermo Scientific) trap column,
75 mm x 2 cm, packed with C18 material, 3 mm, 100 A˚, and separated on an analytical EASY-Spray column (Thermo Scientific,
75 mm 3 500 mm) packed with reverse-phase C18 material (PepMap RSLC, 2 mm, 100 A˚). Peptides were eluted over 110 min at
a flow rate of 300 nL/min. An elution gradient protocol from 2% to 25% B, followed by two steps at 35% B for 5 min and at
95% B for 5 min, respectively, was used.
Heart samples were additionally analyzed using an Orbitrap Q Exactive HF mass spectrometer (Thermo Fisher Scientific) coupled
to a nano EasyLC 1000 (Thermo Fisher Scientific). The peptides were loaded onto a reverse-phase C18 (ReproSil-Pur 120 C18-AQ,
1.9 mm,Dr. Maisch GmbH) packed self-made column (75 mm3 150mm) that was connected to an empty Picotip emitter (NewObjec-
tive, Woburn, MA). Peptides were injected into the MS at a flow rate of 300 nL/min and were separated using a 90min gradient of 2%
to 25% buffer B. The MS was set to acquire full-scan MS spectra (300–1700 m/z) at a resolution of 60,000 after accumulation to an
automated gain control (AGC) target value of 33 106. Charge state screening was enabled, and unassigned charge states and single
charged precursors were excluded. Ions were isolated using a quadrupole mass filter with a 2 m/z isolation window. The maximum
injection time was set to 240 ms and HCD fragmentation was performed at 28% normalized collision energy. Finally, selected ions
were dynamically excluded for 20 s.
QUANTIFICATION AND STATISTICAL ANALYSIS
Raw Mass Spectrometry Data Analysis and Label Free Quantification
MS and MS/MS spectra were converted to Mascot generic format (MGF) by use of Proteome Discoverer, v2.1 (Thermo Fisher Sci-
entific, Bremen, Germany).Whenmultiple fragmentation techniques (HCDand EThcD) were utilized, separateMGF fileswere created
from the raw file for each type of fragmentation. MGF files were further processed (Bilan et al., 2017a). The MGFs were searched
against the UniProtKB mouse database (taxonomy 10090, version 20160902), which included 24’905 Swiss-Prot, 34’616 TrEMBL
entries, 59’783 reverse sequences, and 262 common contaminants.
Mascot 2.5.1.3 (Matrix Science) was used for peptide sequence identification with previously described search settings and some
modification for the EThcD searches (Bilan et al., 2017a). Enzyme specificity was set to trypsin, allowing up to 4 missed cleavages.
The ADP-ribose variable modification was set to a mass shift of 541.0611, with scoring of the neutral losses equal to 347.0631 and
249.0862. The marker ions at m/z 428.0372, 348.0709, 250.0940, 136.0623 were ignored for scoring. Ser, Arg, Lys, Asp and Glu res-
idues were set as variable ADP-ribose acceptor sites. Carbamidomethylation was set as a fixedmodification on C and oxidation as a
variable modification on M. Peptides are considered correctly identified when a Mascot score > 20 and an expectation value < 0.05
are obtained. For the ADP-ribosylation site analyses, peptides identified with EThcD fragmentation, having a mascot localization
score > 90% were used if not stated otherwise.
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To perform label-free quantification based on the MS1 precursor peak area of the identified peptides and proteins, Progenesis QI
software (v. 3.0.6039.34628, Nonlinear Dynamics, Purham, NC) was applied. Raw data were imported into Progenesis and aligned
based on the MS1 peak retention time. All samples were normalized based on the total signal intensity. The obtained results were
exported as MGF and searched with Mascot as indicated above. The Mascot search results were imported into Scaffold software
(v.4.7.2) and filtered for protein and peptide FDR values of 1% and 0.5% respectively. When multiple precursors were observed for
the same peptide, the values were summed up to obtain the total level of the peptide.
Bioinformatic Analyses
Statistical analysis, volcano plot analysis, principal component analysis and hierarchical clusteringwere performed using the Perseus
software suite (Max Planck Institute of Biochemistry, Department of Proteomics and Signal Transduction, Munich). Normalized LFQ
intensities were imported.
For GO enrichment analyses the GOrilla online tool (Eden et al., 2009) was applied, using a C2C12myotube, amouse skeletal mus-
cle or a mouse heart proteome as background (Deshmukh et al., 2015; Lau et al., 2016). A p value threshold of 103 was set and
higher-ranking terms were chosen from GO Biological Processes, GO Molecular Functions, GO Cellular Compartments or Kyoto
Encyclopedia of Genes and Genomes (KEGG) for display.
Protein-protein interactions in between ADP-ribosylated protein were analyzed using the interaction data from the STRING data-
base (v. 10.5) using high confidence interaction scores (R0.7) and hiding disconnected ADP-ribosylated nodes from the network.
Significantly enriched, interesting GO Biological Processes and KEGG pathway terms were annotated according to the STRING
database and GO Cellular Compartments were annotated using the PANTHER database (Mi et al., 2017).
The heart samples measured on the Q Exactive HF MS, using a non-product dependent HCD fragmentation method, were used
to extract MS2 ADP-ribose marker ion patterns from the Mascot ouput.dat files. For this we used the PTM marker finder tool and
following marker ions were included 136.0618, 250.0935, 348.0704, 428.0367 and 584.0901 (Nanni et al., 2013). Only spectra
were considered where at least four marker ions were identified with an intensity of at least 5% of the highest peak and a mascot
score of > 20.
For the ADP-ribosylation site motif analysis we used the web-based motif-x program (Chou and Schwartz, 2011). We included all
Arg-ADPr sites identified with a localization score > 90% for the analysis. A p value threshold < 0.0005 was chosen for the binomial
probability and a 21 amino acid windowwith the ADP-ribosylation site in the center was analyzed against the whole mouse proteome
as a background. All identifiedmotifs were reported as a 13 amino acid window. Their fraction to all analyzed sites is indicated as well
as the motif score. The motif score is the sum of the negative log probabilities used to fix each position of the reported motif. The
higher the score the more statistically significant and specific is the motif.
The protein structure of HPX (Paoli et al., 1999) was visualized and annotated using PyMOL v1.7.4. All Venn diagrams were gener-
ated using biovenn (http://www.biovenn.nl).
DATA AND SOFTWARE AVAILABILITY
Data Availability
The accession number for themass spectrometry proteomics data for the C2C12 cells, the mouse skeletal and heart muscle tissues,
including the RAW files, peak list files (MGFs), and result files (mzIdent) reported in this paper is ProteomeXchange PRIDE:
PXD008041 (10.6019/PXD008041) (Vizcaı´no et al., 2016). The additional data that support the findings of this study are available
from the corresponding author on request.
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